Skip to content
Search

Latest Stories

Mental health leaders call for “comprehensive plan” to tackle growing demand

Leaders running mental health services have called for a comprehensive plan from the government to address the growing demand for mental healthcare in England.

Calling it a sober warning, the leaders said children and young people will have to face longer waits for their treatment absence of a concrete plan, leading to deterioration of their mental health.


Mental health leaders, such as NHS trust chief executives and medical directors have raised concerns that their services, workforce and patients are being sidelined while they face high demand and pressure, just like the rest of the NHS.

The NHS Confederation’s Mental Health Network has called for attention from the government and recovery plan to tackle the growing demand.

Matthew Taylor, chief executive of the NHS Confederation, said: “We are moving towards a new phase of needing to ‘live with’ coronavirus but for a worrying number of people, the virus is leaving a growing legacy of poor mental health that services are not equipped to deal with adequately at present.

“With projections showing that 10 million people in England, including 1.5 million children and teenagers, will need new or additional support for their mental health over the next three to five years it is no wonder that health leaders have dubbed this the second pandemic.

“A national crisis of this scale deserves targeted and sustained attention from the Government in the same way we have seen with the elective care backlog.”

Currently, around 1.6 million people are on the waiting list for specialised mental health treatment, and there are an additional eight million people who could benefit from this line sort of treatment.

The call follows the publication of the long-awaited NHS Elective Recovery Plan, which set out how the backlog of people needing planned surgical procedures will be addressed.

They noted that out of £44 billion of additional funding allocated for the NHS in the government’s Spending Review last year, none was specifically identified for mental health.

According to leaders’ estimate, mental health services would need an extra £1 billion in 2022/23 to keep up with the rising patient demand.

A recovery plan for mental healthcare should include provision of additional support for the mental health workers as they feel close to burnout.

It should also include expansion of estates for specialist mental healthcare, including modernizing dated buildings and equipment, as backed by the Royal College of Psychiatrists recently.

Moreover, new ways should be identified to encourage people to come forward and access support for their mental health.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less